Emergent BioSolutions (EBS) Gross Margin (2011 - 2026)

Emergent BioSolutions' Gross Margin history runs 16 years deep, the most recent figure standing at 53.88% for Q1 2026.

• On a quarterly basis, Gross Margin fell 630.0% year-over-year to 53.88% in Q1 2026; TTM through Mar 2026 was 54.24%, a 408.0% increase from a year earlier, with the FY2025 full-year figure at 56.09%, up 2137.0% from the prior year.
• Gross Margin grew to 53.88% in Q1 2026 per EBS's latest filing, from 42.91% in the prior quarter.
• Across five years, Gross Margin topped out at 73.65% in Q1 2022 and bottomed at 6.94% in Q1 2023.
• The 5-year median for Gross Margin is 50.6% (2022), against an average of 48.05%.
• Across the five-year window, Gross Margin slumped 6672 bps in 2023 and soared 4493 bps in 2024, its largest moves.
• Year by year, Gross Margin stood at 49.33% in 2022, then tumbled by 33 bps to 33.08% in 2023, then increased by 19 bps to 39.39% in 2024, then increased by 9 bps to 42.91% in 2025, then gained by 26 bps to 53.88% in 2026.
• Per Business Quant, the three latest EBS Gross Margin figures stand at 53.88% (Q1 2026), 42.91% (Q4 2025), and 62.83% (Q3 2025).